Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Immatics ( (IMTX) ) has issued an update.
Immatics has announced significant advancements in its clinical pipeline, particularly in the commercialization of PRAME cell therapy for cutaneous melanoma and the expansion into other solid cancer types such as gynecologic cancers. The company is also collaborating with Moderna to develop mRNA-encoded TCER molecules, paving the way for innovative therapeutic solutions. Immatics is strategically positioned to meet its milestones, with a strong cash position anticipated to support its pipeline priorities through 2027, and has initiated the Phase 3 SUPRAME trial targeting a large patient population in both the US and EU5.
More about Immatics
Immatics is a biotechnology company focused on developing T cell-based immunotherapies for cancer patients. The company’s primary products are centered around leveraging the power of T cells to target and treat various solid cancers, including melanoma and gynecologic cancers.
YTD Price Performance: -13.34%
Average Trading Volume: 699,904
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $767.5M
For an in-depth examination of IMTX stock, go to TipRanks’ Stock Analysis page.
